(a) whether the Government has discussed with its US counterparts the situation arising out of US Government’s order of making it mandatory for Active Pharmaceutical Agreements (API) to be manufactured locally;
(b) if so, the details of the discussions;
(c) whether there is any likely solution devised during these discussions to ensure that pharma companies in India are not adversely affected; and
(d) if not, the reasons for not taking the issue with the concerned US department along with the steps taken by the Government to minimize the probable loss the pharma companies may incur in such a situation?